PARP1 and disease arising from reactivation of latent virus: Morgan et al. [63] recently demonstrated the activity of PARP1 in regulating the transcription of viral EBV genes, modulating profiles associated with active and latent infection phases, and although previously proposed by the same research group as a potential treatment strategy for EBV-positive tumors [64], the treatment with PARPi did not show any clinically relevant cytotoxic activity against either cell line.